$BMY News Article - U.S. FDA Accepts for Priority
Post# of 115
(Total Views: 200)
Posted On: 05/01/2023 2:30:47 PM
$BMY News Article - U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) https://marketwirenews.com/news-releases/u-s-...37014.html
(0)
(0)Bristol-Myers Squibb Company (BMY) Stock Research Links
My Twitter: WhyteStocks
Scroll down for more posts ▼